A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.
about
Melioidosis: epidemiology, pathophysiology, and management.CD1d- and MR1-Restricted T Cells in SepsisThe platelet activating factor (PAF) signaling cascade in systemic inflammatory responsesManagement of melioidosisSepsis: in search of cure.A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?Experimental and emerging therapies for sepsis and septic shock.Treatment and prophylaxis of melioidosisRecent developments in the treatment of sepsis.Platelet-activating factor and normal or leukaemic haematopoiesis.In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards Platelet Activating Factor and thrombinRecent developments in the identification of novel therapeutic targets for the treatment of patients with sepsis and septic shock.Relationship between cytokine mRNA expression and organ damage following cecal ligation and puncture.Pharmacological approach to acute pancreatitis.Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology?Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-kappa B (NF-kappa B).Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategy.
P2860
Q24522461-447E93DA-C2FA-4012-BFCD-41C8BE263043Q26796132-97F7B14F-0197-4128-97FB-421AB70A06EEQ27693180-19191D21-1746-4180-B7A4-CBF2997ADBE2Q28245689-54B04A04-C74C-419D-98FF-6B744358BDCDQ30251753-7B61F32A-683D-405D-AE48-71F67B15D198Q33552144-6464E48F-6F9D-417D-80AB-0FAD9700CB0EQ34481636-D67B4CED-62D5-4AD9-9F97-1AB7F29944E0Q34538191-8C7492DF-A7D0-4A98-839B-C147CCEF9B29Q35056046-A4D17AAB-71BB-4340-A72E-8BCDBE4485F5Q35152617-E470D662-5753-4317-B9C5-91DA498738B0Q35183189-302728E8-99CC-48FF-9E4A-A7EEE2CDC488Q35585111-93B91229-CB8E-45B1-8552-0F81DFE9D6F1Q36309067-FFAFD4AC-622C-47DC-BB35-4C2ED5BF9D5FQ37169329-C55F104C-7359-4BC2-9EFB-9F0044C21802Q38133641-F68DE155-C7A1-4015-9E72-4B7E54B3A0E2Q40703735-B2E6865A-95C5-4826-B728-4F7054B0463AQ43007704-ED75E9DF-E97F-4E0D-8C7D-54C7DA49CAFB
P2860
A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
A double-blind placebo-control ...... n patients with severe sepsis.
@en
A double-blind placebo-controlled study of an infusion of lexipafant
@nl
type
label
A double-blind placebo-control ...... n patients with severe sepsis.
@en
A double-blind placebo-controlled study of an infusion of lexipafant
@nl
prefLabel
A double-blind placebo-control ...... n patients with severe sepsis.
@en
A double-blind placebo-controlled study of an infusion of lexipafant
@nl
P2093
P2860
P1476
A double-blind placebo-control ...... in patients with severe sepsis
@en
P2093
C Permpikul
S Intaranongpai
W Chaowagul
Y Suputtamongkol
P2860
P304
P356
10.1128/AAC.44.3.693-696.2000
P407
P577
2000-03-01T00:00:00Z